These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37730912)

  • 1. Albendazole induces an anti-tumor effect and potentiates PD-L1 blockade immunotherapy.
    Zhang W; He Z; Liang F; Gong J; Tan L; Yang J; Song S; Xie L; Lu Y
    J Cancer Res Clin Oncol; 2023 Dec; 149(18):16763-16778. PubMed ID: 37730912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Albendazole induces immunotherapy response by facilitating ubiquitin-mediated PD-L1 degradation.
    Zhu L; Kuang X; Zhang G; Liang L; Liu D; Hu B; Xie Z; Li H; Liu H; Ye M; Chen X; Liu J
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35577504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4
    Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade.
    Singh S; Roszik J; Saini N; Singh VK; Bavisi K; Wang Z; Vien LT; Yang Z; Kundu S; Davis RE; Bover L; Diab A; Neelapu SS; Overwijk WW; Rai K; Singh M
    Front Immunol; 2022; 13():794684. PubMed ID: 35720386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted deletion of CD244 on monocytes promotes differentiation into anti-tumorigenic macrophages and potentiates PD-L1 blockade in melanoma.
    Kim J; Kim TJ; Chae S; Ha H; Park Y; Park S; Yoon CJ; Lim SA; Lee H; Kim J; Kim J; Im K; Lee K; Kim J; Kim D; Lee E; Shin MH; Park SI; Rhee I; Jung K; Lee J; Lee KH; Hwang D; Lee KM
    Mol Cancer; 2024 Feb; 23(1):45. PubMed ID: 38424542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 8. PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors.
    Beyrend G; van der Gracht E; Yilmaz A; van Duikeren S; Camps M; Höllt T; Vilanova A; van Unen V; Koning F; de Miranda NFCC; Arens R; Ossendorp F
    J Immunother Cancer; 2019 Aug; 7(1):217. PubMed ID: 31412943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
    Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1.
    D'Alterio C; Buoncervello M; Ieranò C; Napolitano M; Portella L; Rea G; Barbieri A; Luciano A; Scognamiglio G; Tatangelo F; Anniciello AM; Monaco M; Cavalcanti E; Maiolino P; Romagnoli G; Arra C; Botti G; Gabriele L; Scala S
    J Exp Clin Cancer Res; 2019 Oct; 38(1):432. PubMed ID: 31661001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines.
    Ji S; Lee J; Lee ES; Kim DH; Sin JI
    Hum Vaccin Immunother; 2021 Jul; 17(7):1910-1922. PubMed ID: 33522416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of local radiotherapy and anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) therapy augments PD-L1 blockade-mediated anti-tumor effects in murine breast cancer model.
    Song JY; Han MG; Kim Y; Kim MJ; Kang MH; Jeon SH; Kim IA
    Radiother Oncol; 2024 Jan; 190():109981. PubMed ID: 37925106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 14. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.
    Pilon-Thomas S; Mackay A; Vohra N; Mulé JJ
    J Immunol; 2010 Apr; 184(7):3442-9. PubMed ID: 20194714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-cell RNA sequencing reveals the effects of anti-PD-L1 therapy on 3LL lung cancer model and its tumor microenvironment.
    Zhang H; Huang H; Wu S; He X; Chen J; Zheng X; Chen L; Wang Z
    Med Oncol; 2023 Aug; 40(10):285. PubMed ID: 37653265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma.
    Yan H; Jiang A; Huang Y; Zhang J; Yang W; Zhang W; Liu T
    Front Immunol; 2023; 14():1265914. PubMed ID: 37876940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-methoxyestradiol inhibits melanoma cell growth by activating adaptive immunity.
    Hua W; Huang X; Li J; Feng W; Sun Y; Guo C
    Immunopharmacol Immunotoxicol; 2022 Aug; 44(4):541-547. PubMed ID: 35451929
    [No Abstract]   [Full Text] [Related]  

  • 18. Salvia mitiorrhiza Bunge aqueous extract attenuates infiltration of tumor-associated macrophages and potentiates anti-PD-L1 immunotherapy in colorectal cancer through modulating Cox2/PGE2 cascade.
    Song M; Qian C; Zhang T; Tang Y; Zhou Y; Wei Z; Wang A; Zhong C; Zhao Y; Lu Y
    J Ethnopharmacol; 2023 Nov; 316():116735. PubMed ID: 37286115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.
    Chen X; Wang K; Jiang S; Sun H; Che X; Zhang M; He J; Wen Y; Liao M; Li X; Zhou X; Song J; Ren X; Yi W; Yang J; Chen X; Yin M; Cheng Y
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35347072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.